α-galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor

Journal of Immunology

Volumn 175, Issue 5, 2005, Pages 3309-3317

  Ko, Sung Youl ^a   Ko, Hyun Jeong ^a   Chang, Woo Sung ^a   Park, Se Ho ^b   Kweon, Mi Na ^c   Kang, Chang Yuil ^a  

^a Seoul National University   (South Korea)

^b Korea University   (South Korea)

^c International Vaccine Institute   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CD1D ANTIGEN; CYTOKINE; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INFLUENZA VIRUS HEMAGGLUTININ; LIGAND; LIVE VACCINE; OVALBUMIN; SECRETORY IMMUNOGLOBULIN;

ADENOVIRUS; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CELL LINE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG RESPONSE; EFFECTOR CELL; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION PREVENTION; INFLUENZA; LYMPHOCYTE DIFFERENTIATION; MOUSE; MOUSE STRAIN; MUCOSAL IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TUMOR; VACCINATION; VIRUS INFECTION;

EID: 23844523426     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.5.3309     Document Type: Article

References (45)

1. Czerkinsky, C., F. Anjuere, J. R. McGhee, A. George-Chandy, J. Holmgren, M. P. Kieny, K. Fujiyashi, J. F. Mestecky, V. Pierrefite-Carle, C. Rask, and J. B. Sun. 1999. Mucosal immunity and tolerance: relevance to vaccine development. Immunol. Rev, 170: 197-222.
2. Belyakov, I. M., M. A. Derby, J. D. Ahlers, B. L. Kelsall, P. Earl, B. Moss, W. Strober, and J. A. Berzofsky. 1998. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc. Natl. Acad. Sci. USA 95: 1709-1714.
3. Berzofsky, J. A., J. D. Ahlers, and I. M. Belyakov. 2001. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 1: 209-219.
4. Kozlowski, P. A., and M. R. Neutra. 2003. The role of mucosal immunity in prevention of HIV transmission. Curr. Mol. Med. 3: 217-228.
5. Yuki, Y., and H. Kiyono. 2003. New generation of mucosal adjuvants for the induction of protective immunity. Rev. Med. Virol 13: 293-310.
6. Kawano, T., J. Cui, Y. Koezuka, I. Toura, Y. Kaneko, K. Motoki, H. Ueno, R. Nakagawa, H. Sato, E. Kondo, et al. 1997. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 278: 1626-1629.
7. + T cells produce large amounts of IL-4 and IFN-γ upon activation by anti-CD3 or CD1. J. Immunol. 159: 2240-2249.
8. Wilson, M. T., C. Johansson, D. Olivares-Villagomez, A. K. Singh, A. K. Stanic, C. R. Wang, S. Joyce, M. J. Wick, and L. Van Kaer. 2003. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc. Natl. Acad. Sci. USA 100: 10913-10918.
9. Gonzalez-Aseguinolaza, G., L. Van Kaer, C. C. Bergmann, J. M. Wilson, J. Schmieg, M. Kronenberg, T. Nakayama, M. Taniguchi, Y. Koezuka, and M. Tsuji. 2002. Natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195: 617-624.
10. Hong, S., M. T. Wilson, I. Serizawa, L. Wu, N. Singh, O. V. Naidenko, T. Miura, T. Haba, D. C. Scherer, J. Wei, et al. 2001. The natural killer T-cell ligand Q-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 7: 1052-1056.
11. Sharif, S., G. A. Arreaza, P. Zucker, Q. S. Mi, J. Sondhi, O. V. Naidenko, M. Kronenberg, Y. Koezuka, T. L. Delovitch, J. M. Gombert, et al. 2001. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes. Nat. Med. 7: 1057-1062.
12. Singh, A. K., M. T. Wilson, S. Hong, D. Olivares-Villagomez, C. Du, A. K. Stanic, S. Joyce, S. Sriram, Y. Koezuka, and L. Van Kaer. 2001. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194: 1801-1811.
13. Teige, A., I. Teige, S. Lavasani, R. Bockermann, E. Mondoc, R. Holmdahl, and S. Issazadeh-Navikas. 2004. CD1-dependent regulation of chronic central nervous system inflammation in experimental autoimmune encephalomyelitis. J. Immunol. 172: 186-194.
14. + T cells in a TH2 response and in immunoglobulin E production. Science 270: 1845-1847.
15. Singh, N., S. Hong, D. C. Scherer, I. Serizawa, N. Burdin, M. Kronenberg, Y. Koezuka, and L. Van Kaer. 1999. Cutting edge: activation of NK T cells by CD1d and α-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. J. Immunol. 163: 2373-2377.
16. Laloux, V., L. Beaudoin, D. Jeske, C. Camaud, and A. Lehuen. 2001. NK T cell-induced protection against diabetes in Vα14-Jα281 transgenic nonobese diabetic mice is associated with a Th2 shift circumscribed regionally to the islets and functionally to islet autoantigen. J. Immunol. 166: 3749-3756.
17. + T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J. Immunol. 171: 5140-5147.
18. + T cells in vivo. J. Immunol. 170: 2540-2548.
19. Fujii, S., K. Shimizu, C. Smith, L. Bonifaz, and R. M. Steinman. 2003. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CDS T cell immunity to a coadministered protein. J. Exp. Med. 198: 267-279.
20. Fujii, S., K. Liu, C. Smith, A. J. Bonito, and R. M. Steinman. 2004. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J. Exp. Med. 199: 1607-1618.
21. Chung, Y., W. S. Chang, S. Kim, and C. Y. Kang. 2004. NKT cell ligand α-galactosylceramide blocks the induction of oral tolerance by triggering dendritic cell maturation. Eur. J. Immunol. 34: 2471-2479.
22. Gonzalez-Aseguinolaza, G., C. de Oliveira, M. Tomaska, S. Hong, O. Bruna-Romero, T. Nakayama, M. Taniguchi, A. Bendelac, L. Van Kaer, Y. Koezuka, and M. Tsuji. 2000. α-Galactosylceramide-activated Vα14 natural killer T cells mediate protection against murine malaria. Proc. Natl. Acad. Sci. USA 97: 8461-8466.
23. van Ginkel, F. W., R. J. Jackson, Y. Yuki, and J. R. McGhee. 2000. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165: 4778-4782.
24. Romeo, V. D., J. deMeireles, A. P. Sileno, H. K. Pimplaskar, and C. R. Behl. 1998. Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv. Drug Deliv. Rev. 29; 89-116.
25. Davenport, F. M., A. V. Hennessy, F. M. Brandon, R. G. Webster, C. D. Barrett, Jr., and G. O. Lease. 1964. Comparisons of serologic and febrile responses in humans to vaccination with influenza a viruses or their hemagglutinins. J. Lab. Clin. Med. 63: 5-13.
26. Choi, Y. K., Y. J. Kim, H. S. Park, K. Choi, S. G. Paik, Y. I. Lee, and J. G. Park. 2003. Suppression of glomeruiosclerosis by adenovirus-mediated IL-10 expression in the kidney. Gene Ther. 10: 559-568.
27. Takikawa, H., S.-E. Muto, and K. Mori. 1998. Diastereoselective epoxidation of the double bond at C-4 of sphingosines to provide phytosphingosine relatives such as á-galactosylceramide KRN7000. Tetrahedron 54: 3141.
28. Yamamoto, M., D. E. Briles, S. Yamamoto, M. Ohmura, H. Kiyono, and J. R. McGhee. 1998. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A. J. Immunol. 161:4115-4121.
29. Chung, Y., J. Cho, Y. S. Chang, S. H. Cho, and C. Y. Kang. 2002. Preventive and therapeutic effects of oral tolerance in a murine model of asthma. Immunobiology 206: 408-423.
30. Silk, J. D., I. F. Hermans, U. Gileadi, T. W. Chong, D. Shepherd, M. Salio, B. Mathew, R. R. Schmidt, S. J. Lunt, K. J. Williams, I. J. Stratford, et al. 2004. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. J. Clin. Invest. 114: 1800-1811.
31. Park, S. H., A. Weiss, K. Benlagha, T. Kyin, L. Teyton, and A. Bendelac. 2001. The mouse CD1d-restricted repertoire is dominated by a few autoreactive T cell receptor families. J. Exp. Med. 193: 893-904.
32. Hayakawa, Y., S. P. Berzins, N. Y. Crowe, D. I. Godfrey, and M. S. Smyth. 2004. Antigen-induced tolerance by intrathymic modulation of self-recognizing inhibitory receptors. Nat. Immunol. 5: 590-596.
33. Renegar, K. B., P. A. Small, Jr., L. G. Boykins, and P. F. Wright. 2004. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J. Immunol. 173: 1978-1986.
34. Belyakov, I. M., and J. A. Berzofsky. 2004. Immunobiology of mucosal HIV infection and the basis for development of a new generation of mucosal AIDS vaccines. Immunity 20: 247-253.
35. Nakagawa, R., I. Nagafune, Y. Tazunoki, H. Ehara, H. Tomura, R. Iijima, K. Motoki, M. Kamishohara, and S. Seki. 2001. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by α- galactosylceramide in mice. J. Immunol. 166: 6578-6584.
36. Hayakawa, Y., K. Takeda, H. Yagita, S. Kakuta, Y. Iwakura, L. Van Kaer, I. Saiki, and K. Okumura. 2001. Critical contribution of IFN-γ and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of α-galactosylceramide. Eur. J. Immunol. 31: 1720-1727.
37. Hayakawa, Y., K. Takeda, H. Yagita, M. J. Smyth, L. Van Kaer, K. Okumura, and I. Saiki. 2002. IFN-γ-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, α-galactosylceramide. Blood 100: 1728-1733.
38. Wolvers, D. A., C. J. Coenen-de Roo, R. E. Mebius, M. J. van der Cammen, F. Tirion, A. M. Miltenburg, and G. Kraal. 1999. Intranasally induced immunological tolerance is determined by characteristics of the draining lymph nodes: studies with OVA and human cartilage gp-39. J. Immunol. 162: 1994-1998.
39. + T cells. J. Immunol. 163: 2592-2600.
40. + T cells in airway inflammation and tolerance. J. Immunol. 174: 854-863.
41. Gumperz, J. E., S. Miyake, T. Yamamura, and M. B. Brenner. 2002. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195: 625-636.
42. + NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103: 383-389.
43. Giaccone, G., C. J. Punt, Y. Ando, R. Ruijter, N. Nishi, M. Peters, B. M. von Blomberg, R. J. Scheper, H. J. van der Vliet, A. J. van den Eertwegh, et al. 2002. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors, Clin. Cancer Res. 8: 3702-3709.
44. Osman, Y., T. Kawamura, T. Naito, K. Takeda, L. Van Kaer, K. Okumura, and T. Abo. 2000. Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide. Eur. J. Immunol. 30: 1919-1928.
45. Belshe, R. B., P. M. Mendelman, J. Treanor, J. King, W. C. Gruber, P. Piedra, D. I. Bernstein, F. G. Hayden, K. Kotloff, K. Zangwill, et al. 1998. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 338: 1405-1412.